InvestorsHub Logo
Followers 42
Posts 1152
Boards Moderated 0
Alias Born 03/24/2021

Re: foxi post# 128087

Monday, 09/27/2021 3:07:15 PM

Monday, September 27, 2021 3:07:15 PM

Post# of 198650
More Savov research:

Godfather posted this document in one of the ENZC discord chats. https://cdn.discordapp.com/attachments/795853537548435499/891016669508550667/Screenshot_20210924-134128_Chrome.jpg (Also shown inline at EOM)

The document spells out that Immunotech agrees to "exclusively license from The Zhabilov Trust all of The Zhabilov Trust's rights under patents, patent applications and know-how" related to IPF.

In my earlier post I quoted the following from one of ENZC's latest filings regarding the scope of the exclusive licensing:

On June 22, 2017, Eco Petroleum Solutions, Inc. (OTC Markets "ECPO" or the “Company”) announces that IMMB BG, a subsidiary of Immunotech Laboratories, Inc., the Company’s subsidiary, has issued an exclusive Distribution Agreement (the “Agreement”) for the territory of the Ukraine to LLC Project Development and Implementation Centre Omega (“Omega”). The term of the agreement is for an initial ten-year period with an option to renew the agreement for an additional ten years. The Agreement establishes a price of €3,300 (Euros) per one 8-week cycle of injections or 16 vials. The treatment protocol requires two 8-week cycles of injections administered twice a week with a one-week break between cycles. The ITV-1 treatment will be administered with a combination of different variations of Protease Inhibitors used in the treatment of HIV/AIDS.


It looks like two agreements happened here, one with IMMB for exclusive license to everything related to the patented HIV treatment and another territorial distribution agreement much later with "LLC Project Development and Implementation Centre Omega" for Ukraine only. There's a gap in my knowledge from this time period so I'm not sure yet what agreements changed later or came after. I'm also not sure where GF's copy of this agreement came from.

What it does seem to suggest is that Immunotech at some point held an exclusive worldwide license to everything related to Harry's IPF patent, as well as an agreement about royalties for worldwide gross revenue. IMMB BG was a subsidiary of IMMB and was able to issue the exclusive distribution agreement with Omega in 2017. In light of how closely IMMB and IMMB BG were related and that IMMB BG could clearly issue sublicenses in 2017, it's important to keep looking to learn which of the worldwide exclusive rights to all of Harry's IPF patent rights might have been exposed to bad players in IMMB BG.

At this time we know ENZC is the one suing Savov and not vice versa, and Savov looks to have taken questionable actions outside of the legal system. But can Savov produce an old agreement that would help his defense?

Hoping to find that IMMB BG had an exclusive regional license at most and permission to sublicense within the same region.

Still digging!